



Rebiopsy for patients with progression events
n=19

Figure S1 Repeat biopsy samples for patients with progression events (n=19). 26.3% of patients did not undergo repeat biopsy beyond progression.

Table S1 Baseline characteristics of patients with longer and shorter EML4 fusion variants

Baseline characteristics	Longer variants (n=33) vs. shorter variants (n=16)
Sex (female)	57.6% vs. 75%; P=0.346
Age (<65 years)	81.8% vs. 75%; P=0.709
Smoking history (non-smoker)	78.8% vs. 87.5%; P=0.72
ECOG 0-1	66.7% vs. 62.5%; P=1
Distant metastases (yes)	93.9% vs. 87.5%; P=0.588
Extrathoracic metastases (yes)	60.6% vs. 62.5%; P=1
CNS metastases (yes)	24.2% vs. 12.5%; P=0.464
No. of distant organs involved ≥ 3	30.3% vs. 37.5%; P=0.748

ECOG, Eastern Cooperative Oncology Group Performance Status; CNS, central nervous system.